<DOC>
	<DOCNO>NCT01366638</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety TMC435 combination peginterferon alfa-2b ribavirin chronic genotype 1 hepatitis C virus ( HCV ) -infected participant treatment-naive treatment-experienced ( prior relapser non-responder Interferon-based therapy ) Japan .</brief_summary>
	<brief_title>A Study TMC435 Participants With Genotype 1 Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description>This open-label study ( people involve know identity intervention ) evaluate efficacy safety TMC435 ( also refer jnj-38733214-aaa ) combination standard care therapy ( SoC : peginterferon [ pegIFN ] alfa-2b ribavirin ) adult , genotype 1 hepatitis C virus ( HCV ) -infected participant treatment-naive ( never receive treatment HCV ) , prior relapsers ( relapse previous interferon [ IFN ] -based therapy ) , non-responders ( fail respond previous IFN-based therapy ) Japan . The study objective evaluate efficacy , safety , pharmacokinetics TMC435 . A sufficient number participant treatment-naive , prior relapsers treatment IFN-based therapy , prior non-responders treatment IFN-based therapy enrol assign 1 3 panel ( refer treatment group ) . Participants treatment-naive prior relapsers IFN-based therapy receive 12 week treatment TMC435 ( 100 mg ) daily pegIFN alfa-2b ribavirin ( PR ) follow additional 12 24 week treatment PR . Participants non-responders IFN-based therapy receive 12 week treatment TMC435 ( 100 mg ) daily PR follow additional 36 week treatment PR . TMC435 100-mg capsule take orally mouth . The SoC treatment consist Pegylated interferon ( PegIFN alpha-2b ) ( 1.5 mcg/kg ) inject syringe subcutaneously ( skin ) weekly ribavirin 200-mg capsule ( daily dose : 600-1000 mg base body weight ) take orally mouth 2 time day meal 24 48 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Patient must chronic genotype 1 HCV infection HCV RNA level &gt; = 5.0 log10 IU/mL Patient never receive treatment HCV ( treatmentnaive ) , relapse previous IFNbased therapy ( prior relapser ) fail respond previous IFNbased therapy ( nonresponder ) Patient must willing use contraceptive measure time inform consent 6 month last dose study medication . Coinfection HCV genotype coinfection human immunodeficiency virus ( HIV ) Diagnosed hepatic cirrhosis hepatic failure A medical condition contraindication pegIFN ribavirin therapy History , current medical condition , could impact safety patient study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>TMC435</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Interferon Alfa-2b</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Viral ribonucleic acid</keyword>
</DOC>